CN103834053A - 一种可注射的交联透明质酸凝胶及其制备方法 - Google Patents
一种可注射的交联透明质酸凝胶及其制备方法 Download PDFInfo
- Publication number
- CN103834053A CN103834053A CN201410074850.6A CN201410074850A CN103834053A CN 103834053 A CN103834053 A CN 103834053A CN 201410074850 A CN201410074850 A CN 201410074850A CN 103834053 A CN103834053 A CN 103834053A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- solution
- swelling
- linked
- cross
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 229
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 157
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 154
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000001879 gelation Methods 0.000 title description 4
- 230000008961 swelling Effects 0.000 claims abstract description 48
- 238000004132 cross linking Methods 0.000 claims abstract description 37
- 238000001035 drying Methods 0.000 claims abstract description 24
- 238000011049 filling Methods 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 19
- 239000000839 emulsion Substances 0.000 claims abstract description 18
- 230000001954 sterilising effect Effects 0.000 claims abstract description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 9
- 239000007853 buffer solution Substances 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 claims description 87
- 239000000243 solution Substances 0.000 claims description 52
- 206010042674 Swelling Diseases 0.000 claims description 47
- 239000003795 chemical substances by application Substances 0.000 claims description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 238000009826 distribution Methods 0.000 claims description 25
- 238000010438 heat treatment Methods 0.000 claims description 23
- 239000012074 organic phase Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 238000004945 emulsification Methods 0.000 claims description 17
- -1 glycidol ethers Chemical class 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 14
- YWGKLJXXVGSTCN-UHFFFAOYSA-N [Na].P(O)(O)(O)=O.[Cl] Chemical compound [Na].P(O)(O)(O)=O.[Cl] YWGKLJXXVGSTCN-UHFFFAOYSA-N 0.000 claims description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 102000008186 Collagen Human genes 0.000 claims description 11
- 108010035532 Collagen Proteins 0.000 claims description 11
- 239000008215 water for injection Substances 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 8
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 239000012298 atmosphere Substances 0.000 claims description 7
- 238000000502 dialysis Methods 0.000 claims description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 7
- 229960004194 lidocaine Drugs 0.000 claims description 7
- 230000007935 neutral effect Effects 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 239000003637 basic solution Substances 0.000 claims description 6
- 230000000975 bioactive effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 239000012266 salt solution Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 5
- SYEWHONLFGZGLK-UHFFFAOYSA-N 2-[1,3-bis(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COCC(OCC1OC1)COCC1CO1 SYEWHONLFGZGLK-UHFFFAOYSA-N 0.000 claims description 4
- UUODQIKUTGWMPT-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)pyridine Chemical compound FC1=CC=C(C(F)(F)F)C=N1 UUODQIKUTGWMPT-UHFFFAOYSA-N 0.000 claims description 4
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 4
- 235000019800 disodium phosphate Nutrition 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229920000223 polyglycerol Polymers 0.000 claims description 4
- 229920002545 silicone oil Polymers 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- WTYYGFLRBWMFRY-UHFFFAOYSA-N 2-[6-(oxiran-2-ylmethoxy)hexoxymethyl]oxirane Chemical compound C1OC1COCCCCCCOCC1CO1 WTYYGFLRBWMFRY-UHFFFAOYSA-N 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 claims description 2
- LSWYGACWGAICNM-UHFFFAOYSA-N 2-(prop-2-enoxymethyl)oxirane Chemical compound C=CCOCC1CO1 LSWYGACWGAICNM-UHFFFAOYSA-N 0.000 claims description 2
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical group C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims description 2
- KUAUJXBLDYVELT-UHFFFAOYSA-N 2-[[2,2-dimethyl-3-(oxiran-2-ylmethoxy)propoxy]methyl]oxirane Chemical compound C1OC1COCC(C)(C)COCC1CO1 KUAUJXBLDYVELT-UHFFFAOYSA-N 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- 239000008157 edible vegetable oil Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000007924 injection Substances 0.000 abstract description 33
- 238000002347 injection Methods 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 20
- 238000006731 degradation reaction Methods 0.000 abstract description 18
- 230000015556 catabolic process Effects 0.000 abstract description 15
- 238000005516 engineering process Methods 0.000 abstract description 11
- 239000007943 implant Substances 0.000 abstract description 11
- 230000037303 wrinkles Effects 0.000 abstract description 9
- 238000005469 granulation Methods 0.000 abstract description 6
- 230000003179 granulation Effects 0.000 abstract description 6
- 238000007920 subcutaneous administration Methods 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 5
- 239000003431 cross linking reagent Substances 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 230000009759 skin aging Effects 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract 4
- 210000004207 dermis Anatomy 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
- 239000000047 product Substances 0.000 description 39
- 239000000463 material Substances 0.000 description 8
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 230000003796 beauty Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 150000001718 carbodiimides Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 239000007863 gel particle Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 229920001954 Restylane Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 231100000429 cutaneous necrosis Toxicity 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000004033 diameter control Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410074850.6A CN103834053B (zh) | 2014-02-28 | 2014-02-28 | 一种可注射的交联透明质酸凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410074850.6A CN103834053B (zh) | 2014-02-28 | 2014-02-28 | 一种可注射的交联透明质酸凝胶及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103834053A true CN103834053A (zh) | 2014-06-04 |
CN103834053B CN103834053B (zh) | 2016-04-27 |
Family
ID=50797973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410074850.6A Active CN103834053B (zh) | 2014-02-28 | 2014-02-28 | 一种可注射的交联透明质酸凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103834053B (zh) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104189952A (zh) * | 2014-08-05 | 2014-12-10 | 北京爱美客生物科技有限公司 | 纠正皮肤褶皱注射液及其制备方法 |
CN105949478A (zh) * | 2016-05-05 | 2016-09-21 | 广东东阳光药业有限公司 | 除去交联透明质酸中交联剂的方法 |
CN106074213A (zh) * | 2016-06-24 | 2016-11-09 | 上海建华精细生物制品有限公司 | 用于水光注射的透明质酸钠凝胶及其制备方法和应用 |
CN106139258A (zh) * | 2015-04-08 | 2016-11-23 | 上海昊海生物科技股份有限公司 | 一种管道化制备无菌医用透明质酸钠凝胶的方法 |
CN106267336A (zh) * | 2016-08-31 | 2017-01-04 | 陕西佰傲再生医学有限公司 | 一种骨修复材料及其制备方法 |
CN107189119A (zh) * | 2017-07-24 | 2017-09-22 | 苏州景卓生物技术有限公司 | 一种复合玻尿酸胶原蛋白水凝胶的制备方法及其应用 |
CN107308494A (zh) * | 2017-07-27 | 2017-11-03 | 北京华信佳音医疗科技发展有限责任公司 | 一种注射用胶原蛋白、制备方法及填充剂 |
CN107880288A (zh) * | 2017-11-29 | 2018-04-06 | 桂林华诺威生物科技有限公司 | 一种透明质酸钠凝胶的制备方法 |
CN108543215A (zh) * | 2018-04-20 | 2018-09-18 | 威海迈尼生物科技有限公司 | 一种溶胀型交联透明质酸微针及其制备方法 |
CN108602898A (zh) * | 2016-01-29 | 2018-09-28 | 韩美药品株式会社 | 交联透明质酸的组合及其制备方法 |
CN109010912A (zh) * | 2018-09-27 | 2018-12-18 | 福建拓烯新材料科技有限公司 | 一种改性的玻尿酸可注射填充材料及其制备方法 |
CN109897203A (zh) * | 2017-12-11 | 2019-06-18 | 杭州科腾生物制品有限公司 | 一种直线交联透明质酸制备方法 |
CN110114373A (zh) * | 2016-12-28 | 2019-08-09 | 株式会社柳英制药 | 交联透明质酸凝胶纯化方法 |
CN110300569A (zh) * | 2017-01-12 | 2019-10-01 | 洛斯坦制药有限责任公司 | 可用作注射填充剂和胶原蛋白生长支架的水包硅油组合物 |
CN110573189A (zh) * | 2017-02-28 | 2019-12-13 | Cg生物技术有限公司 | 皮肤注入用组合物 |
CN110573190A (zh) * | 2017-02-28 | 2019-12-13 | Cg生物技术有限公司 | 皮肤注入用组合物 |
CN110621294A (zh) * | 2017-05-18 | 2019-12-27 | 拜奥希医药公司 | 制备水性透明质酸凝胶的方法 |
CN110621355A (zh) * | 2017-02-28 | 2019-12-27 | Cg生物技术有限公司 | 皮肤注入用组合物 |
CN111840638A (zh) * | 2020-07-21 | 2020-10-30 | 华熙生物科技股份有限公司 | 一种注射用交联透明质酸填充剂的制备方法 |
US20210022981A1 (en) * | 2019-07-24 | 2021-01-28 | Amorepacific Corporation | Hyaluronic acid composition for external use on skin and a method for skin moisturizing comprising applying the same onto the skin |
CN112442199A (zh) * | 2019-08-29 | 2021-03-05 | 上海其胜生物制剂有限公司 | 一种具有柔韧性的高稳态凝胶及其制备方法 |
CN113144288A (zh) * | 2021-04-26 | 2021-07-23 | 磐升瑞祥(山东)生物工程有限公司 | 一种复合多组分的胶原蛋白微乳填充剂及其制备方法 |
CN113214511A (zh) * | 2020-01-21 | 2021-08-06 | 华熙生物科技股份有限公司 | 一种彩色交联透明质酸钠凝胶以及凝胶颗粒的制备方法 |
CN113214499A (zh) * | 2020-01-21 | 2021-08-06 | 华熙生物科技股份有限公司 | 一种彩色重度交联透明质酸凝胶以及凝胶颗粒的制备方法 |
CN113413484A (zh) * | 2021-06-21 | 2021-09-21 | 浙江苏嘉医疗器械股份有限公司 | 可用于人体软组织填充的植入材料 |
CN113603903A (zh) * | 2021-08-04 | 2021-11-05 | 上海曜爱生物科技有限公司 | 一种可填充用的丝素蛋白凝胶的制备及应用 |
CN113952510A (zh) * | 2021-11-09 | 2022-01-21 | 无锡本物医疗器械有限公司 | 一种靶向注射型填充剂组合物及其制备方法和应用 |
CN114042189A (zh) * | 2021-11-09 | 2022-02-15 | 无锡本物医疗器械有限公司 | 一种注射型填充剂组合物及其制备方法和应用 |
CN115154665A (zh) * | 2022-06-08 | 2022-10-11 | 浙江驭远生物科技有限公司 | 含重组iii型人源胶原蛋白的润滑液、填充剂及其应用 |
CN115304788A (zh) * | 2022-07-08 | 2022-11-08 | 浙江工业大学 | 一种负载聚乳酸的透明质酸水凝胶及其制备方法与应用 |
WO2023125686A1 (en) * | 2021-12-28 | 2023-07-06 | Shanghai Qisheng Biological Preparation Co., Ltd. | Soft tissue augmentation using injectable, neutral ph soluble collagen-glycosaminoglycan compositions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101502676A (zh) * | 2008-02-04 | 2009-08-12 | 山东省药学科学院 | 一种注射用聚甲基丙烯酸甲酯和交联透明质酸混合凝胶及其制备方法 |
CN103450490A (zh) * | 2013-09-10 | 2013-12-18 | 杭州协合医疗用品有限公司 | 一种以透明质酸钠为原料制备交联透明质酸钠微球凝胶的工艺 |
-
2014
- 2014-02-28 CN CN201410074850.6A patent/CN103834053B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101502676A (zh) * | 2008-02-04 | 2009-08-12 | 山东省药学科学院 | 一种注射用聚甲基丙烯酸甲酯和交联透明质酸混合凝胶及其制备方法 |
CN103450490A (zh) * | 2013-09-10 | 2013-12-18 | 杭州协合医疗用品有限公司 | 一种以透明质酸钠为原料制备交联透明质酸钠微球凝胶的工艺 |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104189952B (zh) * | 2014-08-05 | 2017-03-15 | 爱美客技术发展股份有限公司 | 纠正皮肤褶皱注射液及其制备方法 |
CN104189952A (zh) * | 2014-08-05 | 2014-12-10 | 北京爱美客生物科技有限公司 | 纠正皮肤褶皱注射液及其制备方法 |
CN106139258B (zh) * | 2015-04-08 | 2019-03-26 | 上海昊海生物科技股份有限公司 | 一种管道化制备无菌医用透明质酸钠凝胶的方法 |
CN106139258A (zh) * | 2015-04-08 | 2016-11-23 | 上海昊海生物科技股份有限公司 | 一种管道化制备无菌医用透明质酸钠凝胶的方法 |
CN108602898A (zh) * | 2016-01-29 | 2018-09-28 | 韩美药品株式会社 | 交联透明质酸的组合及其制备方法 |
CN105949478A (zh) * | 2016-05-05 | 2016-09-21 | 广东东阳光药业有限公司 | 除去交联透明质酸中交联剂的方法 |
CN105949478B (zh) * | 2016-05-05 | 2021-10-01 | 宜昌东阳光生化制药有限公司 | 除去交联透明质酸中交联剂的方法 |
CN106074213A (zh) * | 2016-06-24 | 2016-11-09 | 上海建华精细生物制品有限公司 | 用于水光注射的透明质酸钠凝胶及其制备方法和应用 |
CN106267336A (zh) * | 2016-08-31 | 2017-01-04 | 陕西佰傲再生医学有限公司 | 一种骨修复材料及其制备方法 |
CN110114373A (zh) * | 2016-12-28 | 2019-08-09 | 株式会社柳英制药 | 交联透明质酸凝胶纯化方法 |
CN110114373B (zh) * | 2016-12-28 | 2022-03-01 | 株式会社柳英制药 | 交联透明质酸凝胶纯化方法 |
CN110300569B (zh) * | 2017-01-12 | 2023-01-03 | 罗利亚制药有限责任公司 | 可用作注射填充剂和胶原蛋白生长支架的水包硅油组合物 |
CN110300569A (zh) * | 2017-01-12 | 2019-10-01 | 洛斯坦制药有限责任公司 | 可用作注射填充剂和胶原蛋白生长支架的水包硅油组合物 |
CN110573190B (zh) * | 2017-02-28 | 2022-01-25 | Cg生物技术有限公司 | 皮肤注入用组合物 |
CN110573189B (zh) * | 2017-02-28 | 2022-01-25 | Cg生物技术有限公司 | 皮肤注入用组合物 |
CN110621355B (zh) * | 2017-02-28 | 2022-01-21 | Cg生物技术有限公司 | 皮肤注入用组合物 |
CN110573189A (zh) * | 2017-02-28 | 2019-12-13 | Cg生物技术有限公司 | 皮肤注入用组合物 |
CN110573190A (zh) * | 2017-02-28 | 2019-12-13 | Cg生物技术有限公司 | 皮肤注入用组合物 |
US11123455B2 (en) * | 2017-02-28 | 2021-09-21 | Cg Bio Co., Ltd. | Composition for dermal injection |
CN110621355A (zh) * | 2017-02-28 | 2019-12-27 | Cg生物技术有限公司 | 皮肤注入用组合物 |
CN110621294A (zh) * | 2017-05-18 | 2019-12-27 | 拜奥希医药公司 | 制备水性透明质酸凝胶的方法 |
CN107189119B (zh) * | 2017-07-24 | 2020-06-16 | 浙江景嘉医疗科技有限公司 | 一种复合玻尿酸胶原蛋白水凝胶的制备方法及其应用 |
CN107189119A (zh) * | 2017-07-24 | 2017-09-22 | 苏州景卓生物技术有限公司 | 一种复合玻尿酸胶原蛋白水凝胶的制备方法及其应用 |
CN107308494A (zh) * | 2017-07-27 | 2017-11-03 | 北京华信佳音医疗科技发展有限责任公司 | 一种注射用胶原蛋白、制备方法及填充剂 |
CN107880288A (zh) * | 2017-11-29 | 2018-04-06 | 桂林华诺威生物科技有限公司 | 一种透明质酸钠凝胶的制备方法 |
CN109897203A (zh) * | 2017-12-11 | 2019-06-18 | 杭州科腾生物制品有限公司 | 一种直线交联透明质酸制备方法 |
CN108543215A (zh) * | 2018-04-20 | 2018-09-18 | 威海迈尼生物科技有限公司 | 一种溶胀型交联透明质酸微针及其制备方法 |
CN109010912B (zh) * | 2018-09-27 | 2021-05-25 | 福建拓烯新材料科技有限公司 | 一种改性的玻尿酸可注射填充材料及其制备方法 |
CN109010912A (zh) * | 2018-09-27 | 2018-12-18 | 福建拓烯新材料科技有限公司 | 一种改性的玻尿酸可注射填充材料及其制备方法 |
US20210022981A1 (en) * | 2019-07-24 | 2021-01-28 | Amorepacific Corporation | Hyaluronic acid composition for external use on skin and a method for skin moisturizing comprising applying the same onto the skin |
CN112442199B (zh) * | 2019-08-29 | 2023-01-10 | 上海其胜生物制剂有限公司 | 一种具有柔韧性的高稳态凝胶及其制备方法 |
CN112442199A (zh) * | 2019-08-29 | 2021-03-05 | 上海其胜生物制剂有限公司 | 一种具有柔韧性的高稳态凝胶及其制备方法 |
CN113214511A (zh) * | 2020-01-21 | 2021-08-06 | 华熙生物科技股份有限公司 | 一种彩色交联透明质酸钠凝胶以及凝胶颗粒的制备方法 |
CN113214499A (zh) * | 2020-01-21 | 2021-08-06 | 华熙生物科技股份有限公司 | 一种彩色重度交联透明质酸凝胶以及凝胶颗粒的制备方法 |
CN111840638A (zh) * | 2020-07-21 | 2020-10-30 | 华熙生物科技股份有限公司 | 一种注射用交联透明质酸填充剂的制备方法 |
CN111840638B (zh) * | 2020-07-21 | 2022-04-12 | 华熙生物科技股份有限公司 | 一种注射用交联透明质酸填充剂的制备方法 |
CN113144288A (zh) * | 2021-04-26 | 2021-07-23 | 磐升瑞祥(山东)生物工程有限公司 | 一种复合多组分的胶原蛋白微乳填充剂及其制备方法 |
CN113413484A (zh) * | 2021-06-21 | 2021-09-21 | 浙江苏嘉医疗器械股份有限公司 | 可用于人体软组织填充的植入材料 |
CN113413484B (zh) * | 2021-06-21 | 2023-02-10 | 浙江苏嘉医疗器械股份有限公司 | 可用于人体软组织填充的植入材料 |
CN113603903A (zh) * | 2021-08-04 | 2021-11-05 | 上海曜爱生物科技有限公司 | 一种可填充用的丝素蛋白凝胶的制备及应用 |
CN113603903B (zh) * | 2021-08-04 | 2023-10-10 | 上海曜爱生物科技有限公司 | 一种可填充用的丝素蛋白凝胶的制备及应用 |
CN114042189A (zh) * | 2021-11-09 | 2022-02-15 | 无锡本物医疗器械有限公司 | 一种注射型填充剂组合物及其制备方法和应用 |
CN113952510A (zh) * | 2021-11-09 | 2022-01-21 | 无锡本物医疗器械有限公司 | 一种靶向注射型填充剂组合物及其制备方法和应用 |
WO2023125686A1 (en) * | 2021-12-28 | 2023-07-06 | Shanghai Qisheng Biological Preparation Co., Ltd. | Soft tissue augmentation using injectable, neutral ph soluble collagen-glycosaminoglycan compositions |
CN115154665A (zh) * | 2022-06-08 | 2022-10-11 | 浙江驭远生物科技有限公司 | 含重组iii型人源胶原蛋白的润滑液、填充剂及其应用 |
CN115154665B (zh) * | 2022-06-08 | 2024-01-19 | 浙江驭远生物科技有限公司 | 含重组iii型人源胶原蛋白的润滑液、填充剂及其应用 |
CN115304788A (zh) * | 2022-07-08 | 2022-11-08 | 浙江工业大学 | 一种负载聚乳酸的透明质酸水凝胶及其制备方法与应用 |
CN115304788B (zh) * | 2022-07-08 | 2023-09-29 | 浙江工业大学 | 一种负载聚乳酸的透明质酸水凝胶及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103834053B (zh) | 2016-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103834053B (zh) | 一种可注射的交联透明质酸凝胶及其制备方法 | |
CN105126166B (zh) | 注射用含两亲性微球的透明质酸混合凝胶及其制备方法 | |
CN104258470B (zh) | 一种注射用聚乳酸微球和交联透明质酸混合凝胶及其制备方法 | |
CN105358186B (zh) | 交联透明质酸的方法,制备可注射水凝胶的方法,得到的水凝胶,得到的水凝胶的用途 | |
KR101236363B1 (ko) | 연조직 증강을 위한 입자 | |
US11590258B2 (en) | Vitamin C-containing polycaprolactone microsphere filler and preparation method therefor | |
CN104395348B (zh) | 制备基于透明质酸的组合物的方法 | |
CN101918049A (zh) | 原位交联的整体藻酸盐植入物 | |
CN106999635A (zh) | 软骨修复用移植物支架及其制造方法 | |
CN101502676B (zh) | 一种注射用聚甲基丙烯酸甲酯和交联透明质酸混合凝胶及其制备方法 | |
WO2017091017A1 (ko) | 히알루론산 유도체 및 dna 분획물이 포함된 히알루론산 주사용 조성물 및 이의 이용 | |
CN105705137B (zh) | 获得基于含有以粉末形式添加的利多卡因和碱剂的透明质酸且热灭菌的可注射水凝胶的方法 | |
CN104086788A (zh) | 一种注射用修饰透明质酸钠凝胶 | |
CN106397795B (zh) | 一种混合透明质酸凝胶及其制备方法 | |
CN105435308A (zh) | 一种***植入体三维结构及其快速成形方法 | |
CN110121523A (zh) | 在环境温度下可快速交联的有机硅泡沫组合物及其制备和使用方法 | |
CN110300569A (zh) | 可用作注射填充剂和胶原蛋白生长支架的水包硅油组合物 | |
CN114085394A (zh) | 一种重组胶原蛋白双相凝胶及其制备方法和应用 | |
CN107522881A (zh) | 制备单相修饰透明质酸钠凝胶的方法 | |
CN100356990C (zh) | 基于陶瓷的用来注入软组织的可注射植入物 | |
CN108465124A (zh) | 一种自交联注射美容填充材料及制备方法 | |
CN110292655A (zh) | 一种含羟基磷灰石的注射填充制剂及其制备方法 | |
CN110327488A (zh) | 一种注射填充微球制剂及其制备方法 | |
CN102492032A (zh) | 类人胶原蛋白及注射型类人胶原蛋白软组织填充材料 | |
CN106730029A (zh) | 一种注射填充用交联聚谷氨酸凝胶颗粒及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Injectable crosslinked hyaluronic acid gel and preparation method thereof Effective date of registration: 20170207 Granted publication date: 20160427 Pledgee: Xianyang financing guarantee Limited by Share Ltd Pledgor: Shaanxi Boao Regeneration Medical Co., Ltd. Registration number: 2017990000090 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170531 Granted publication date: 20160427 Pledgee: Xianyang financing guarantee Limited by Share Ltd Pledgor: Shaanxi Boao Regeneration Medical Co., Ltd. Registration number: 2017990000090 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Injectable crosslinked hyaluronic acid gel and preparation method thereof Effective date of registration: 20180726 Granted publication date: 20160427 Pledgee: Xianyang corporate finance Company limited by guarantee Pledgor: Shaanxi Boao Regeneration Medical Co., Ltd. Registration number: 2018610000113 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190809 Granted publication date: 20160427 Pledgee: Xianyang corporate finance Company limited by guarantee Pledgor: Shaanxi Boao Regeneration Medical Co., Ltd. Registration number: 2018610000113 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Injectable crosslinked hyaluronic acid gel and preparation method thereof Effective date of registration: 20190809 Granted publication date: 20160427 Pledgee: Xianyang corporate finance Company limited by guarantee Pledgor: Shaanxi Boao Regeneration Medical Co., Ltd. Registration number: Y2019980000032 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201020 Granted publication date: 20160427 Pledgee: Xianyang corporate finance Company limited by guarantee Pledgor: SHAANXI BIO REGENERATION MEDICINE Co.,Ltd. Registration number: Y2019980000032 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Injectable crosslinked hyaluronic acid gel and preparation method thereof Effective date of registration: 20201021 Granted publication date: 20160427 Pledgee: Xianyang corporate finance Company limited by guarantee Pledgor: SHAANXI BIO REGENERATION MEDICINE Co.,Ltd. Registration number: Y2020980006999 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210531 Granted publication date: 20160427 Pledgee: Xianyang corporate finance Company limited by guarantee Pledgor: SHAANXI BIO REGENERATION MEDICINE Co.,Ltd. Registration number: Y2020980006999 |